Contract Research Organization (CRO) Services Market
Report Code
PH 4672
Published in
Apr, 2026, By MarketsandMarkets™
Contract Research Organization (CRO) Services Market by Type (Early Phase, Clinical, Lab, Consulting), Therapeutic Area [Oncology (Breast, Lung), Infectious, Neurology, Vaccines], Modality, Model (FSO, FSP), End User, Competition - Global Forecast to 2031
USD 140.32 BN
MARKET SIZE, 2031
CAGR 8.6%
(2026-2031)
633
REPORT PAGES
883
MARKET TABLES
CRO SERVICES MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global contract research organization (CRO) services market is projected to grow from USD 93.02 billion in 2026 to USD 140.32 billion by 2031, at a CAGR of 8.6% during the forecast period. The market was valued at USD 85.41 billion in 2025. Factors such as the increasing complexity & the growing volume of trials, the rising focus on patient-centric clinical trials such as Decentralized Clinical trials (DCTs), and the flexibility of services offered by CROs are supporting the growth of this market. Growth is also supported by the increasing outsourcing of drug development and clinical research activities by pharmaceutical, biopharmaceutical, and medical device companies.
KEY TAKEAWAYS
-
BY REGIONNorth America is the largest market, accounting for a share of 44.5% in 2025.
-
BY SERVICE TYPEClinical research services accounted for the largest share, at 57.6%, in 2025.
-
BY THERAPEUTIC AREAOncology dominates the market with 35.5% share in 2025.
-
BY END USERMedical device companies are expected to grow at the fastest rate during the forecast period of 2026 to 2031.
-
COMPETITIVE LANDSCAPEMajor market players have adopted both organic and inorganic strategies, including partnerships and investments. Thermo Fisher Scientific Inc. launched the international CorEvitas Adolescent Alopecia Areata (AA) Registry to address a critical unmet need for real-world, adolescent-specific evidence and data on this autoimmune disease.
The CRO services market is witnessing steady growth, driven by factors such as the increasing complexity & the growing volume of trials; the rising focus on patient-centric clinical trials such as Decentralized Clinical trials (DCTs); and the flexibility of services offered by CROs are supporting the growth of this market. Moreover, the upcoming therapeutic drugs patent cliff is fueling pharmaceutical companies to invest heavily in R&D activities and outsource their clinical trials to CROs. Additionally, the growing regulatory focus on patient diversity and data analysis offerings that favor customer reimbursement & market access strategies are other key growth opportunities.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on biopharma clients’ businesses in the CRO services market arises from evolving sponsor demands and changes in global R&D strategy. Pharmaceutical, biotechnology, medical device, and diagnostics companies are the largest users of CRO solutions, with efficient clinical development and regulatory compliance as primary focus areas. Trends such as increased outsourcing, adoption of decentralized and digital clinical trials, and stricter regulatory requirements now directly affect project timelines, budgets, and commercial launch success for sponsors.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Rising trial volume and complexity
-
Growing focus on decentralized/patient-centric trials
RESTRAINTS
Impact
Level
Level
-
No restraints
OPPORTUNITIES
Impact
Level
Level
-
Growing regulatory stringency on the diversity of the patient pool
-
Risk-based monitoring (RBM) and risk-based quality management (RBQM) as a service
CHALLENGES
Impact
Level
Level
-
Patient retention
-
Cybersecurity and intellectual property challenges
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising trial volume and complexity
The steady rise in global clinical trial volume and increasing protocol complexity are key drivers of CRO market growth. More trials target niche populations in oncology, rare diseases, and cell & gene therapies, requiring specialized expertise and broader geographic reach. Protocol designs demand larger datasets, adaptive methodologies, biomarker integration, and real-world evidence collection, significantly expanding operational demands. These complexities push sponsors to outsource to CROs that can provide global site networks, advanced data analytics, and regulatory alignment. By alleviating the resource and infrastructure burden for sponsors, CROs are positioned as essential partners in accelerating trial execution and ensuring compliance across multiple geographies. As pipelines expand and therapeutic science evolves, the reliance on CRO services is expected to deepen, reinforcing their central role in modern drug development.
Opportunity: Growing regulatory stringency on the diversity of the patient pool
Regulatory agencies like the FDA and EMA are increasing requirements for diversity in clinical trials to ensure effective treatments for all populations. The FDA’s 2024 guidelines require trial sponsors to develop Diversity Action Plans (DAPs) to include underrepresented groups, while the EMA’s Clinical Trials Regulation (EU) No. 536/2014 promotes broader participant inclusion. In Europe, the UK HRA/MHRA is piloting Inclusion & Diversity Plans for clinical trials, thereby widening opportunities for CRO partners with community outreach, decentralized models, and real-world data to deliver on these plans across geographies. In response, CROs are enhancing their offerings, creating an opportunity for growth over the forecast period.
Challenge: Patient retention
Patient retention remains a consistent challenge mainly due to burdensome visit schedules, complex protocols, and long study durations. These can derail endpoints. Thus, CROs are building patient-centric programs explicitly to boost engagement and keep participants enrolled. For instance, IQVIA is tackling attrition with digital and in-home support. Its Health Research Space patient app earned a 2025 MedTech Breakthrough Award for engagement, and its Decentralized Trial Suite added Mobile Research Nursing & Phlebotomy to bring visits to the patient, reducing the friction that drives dropouts.
CONTRACT RESEARCH ORGANIZATION SERVICES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
ICON plc provided clinical trial services to the Pfizer and BioNTech SE investigational COVID-19 vaccine programme. | Provided high level of remote clinical monitoring and source data verification, safeguarding data quality and integrity in the evolving pandemic environment |
 |
IQVIA collaborated with Janssen Research & Development, LLC on the Phase 3 COVID-19 vaccine clinical trials | The client leveraged IQVIA's suite of decentralized trial solutions. Employment of telehealth technologies, virtual oversight, and digital patient engagement strategies. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The CRO services market ecosystem comprises contract research organizations (such as IQVIA, ICON, Syneos Health), specialized service providers (for clinical trials, data management, regulatory affairs), and sponsor clients, including pharmaceutical, biotechnology, and medical device companies (like Pfizer, Novartis, and Medtronic). CROs provide essential expertise and infrastructure to design, execute, and manage clinical studies, advancing new therapies from early discovery through regulatory approval. Sponsors rely on CRO partners for cost efficiency, faster timelines, and access to global patient populations, while CROs deliver operational excellence and regulatory compliance. Collaborative partnerships across this value chain are essential for accelerating innovation, lowering development costs, and ensuring success in a highly regulated, competitive life sciences market.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
CRO Services Market, By Service Type
In 2025, clinical research services held the largest share of the CRO services market and will continue leading the market through 2025. The large share of this segment is attributed to the Phase I-IV trial execution, which is the most resource-intensive and cost-driving stage of drug development. Sponsors increasingly rely on CROs for clinical monitoring, site management, patient recruitment, medical writing, pharmacovigilance, and trial operations to accelerate timelines and meet regulatory demands.
CRO Services Market, By Modality
In 2025, small molecules dominated the market. Their large share can be attributed to factors such as the dominance of the pipeline by volume and the loss of exclusivity for patented products. Additionally, the generics and bioequivalence market adds recurring study volume.
CRO Services Market, By Therapeutic area
In 2025, the oncology therapeutic area is expected to dominate the CRO services market. Oncology commands the largest share of CRO services because it remains the most innovation-intensive area in drug development, with pipelines expanding and clinical development productivity improving, fueling sustained trial demand.
REGION
Asia Pacific to be fastest-growing region in global CRO services market during forecast period
The Asia Pacific CRO services market is expected to register the highest CAGR during the forecast period, driven by growth in the pharmaceutical and biopharmaceutical industries, the low cost of conducting clinical trials in the region, favorable government policies, and the rising number of CROs.
CONTRACT RESEARCH ORGANIZATION SERVICES MARKET: COMPANY EVALUATION MATRIX
In the CRO services market matrix, IQVIA (Star) leads with commanding market share and global operational reach, supported by its advanced data analytics, technology-driven clinical trial solutions, and deep expertise serving top pharmaceutical and biotech sponsors. IQVIA’s integrated offerings and extensive global site network make it the preferred partner for large-scale, multi-regional clinical programs. Medpace (Emerging Leader) is rapidly gaining recognition for its specialized focus in specific therapeutic areas, hands-on project management, and high-touch service model tailored to emerging biotechs and mid-sized pharma clients. Through quality execution and niche expertise, Medpace continues to strengthen its competitive position and expand its footprint in key markets.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- IQVIA, Inc.
- ICON Plc.
- Thermo Fisher Scientific Inc.
- Fortrea
- Syneos Health
- LabCorp (US)
- Medpace
- WuXi AppTec
- Frontage Labs
- Pharmaron
- Tigermed
- SGS Société Générale De Surveillance SA.
- Eurofins Scientific
- Linical
- Parexel International Corporation
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 85.41 Billion |
| Market Forecast in 2031 (Value) | USD 140.32 Billion |
| Growth Rate | CAGR of 8.6% from 2026-2031 |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Leading CRO |
|
|
| Leading CRO |
|
|
| SME CRO |
|
|
RECENT DEVELOPMENTS
- March 2026 : IQVIA launched IQVIA.ai, a Unified Agentic AI Platform Powered by NVIDIA to improve efficiency and decision-making across life sciences.
- March 2025 : ICON plc and Mural Health Technologies, Inc. partnered to use the participant management and payments platform, Mural Link.
- January 2024 : Thermo Fisher Scientific Inc. expanded its global laboratory services capabilities with a new bioanalytical lab at GoCo Health Innovation City in Gothenburg, Sweden, serving pharmaceutical and biotech customers with advanced laboratory services and instrumentation across all phases of pharmaceutical development.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
57
2
EXECUTIVE SUMMARY
63
3
PREMIUM INSIGHTS
69
4
MARKET OVERVIEW
Unleash potential in clinical trials with AI, decentralized models, and strategic CRO flexibility.
72
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
RISING TRIAL VOLUME AND COMPLEXITY
4.2.1.2
GROWING FOCUS ON DECENTRALIZED/PATIENT-CENTRIC TRIALS
4.2.1.3
SERVICE FLEXIBILITY OFFERED BY CROS
4.2.1.4
TECHNOLOGICAL INTEGRATIONS
4.2.1.5
GROWING R&D INVESTMENTS AND PRESENCE OF A ROBUST CLINICAL PIPELINE
4.2.2
OPPORTUNITIES
4.2.2.1
GROWING REGULATORY STRINGENCY ON THE DIVERSITY OF THE PATIENT POOL
4.2.2.2
RISK-BASED MONITORING (RBM) AND RISK-BASED QUALITY MANAGEMENT AS A SERVICE
4.2.2.3
OFFERING DATA ANALYSIS OUTCOMES FAVORING CLIENTS’ REIMBURSEMENT AND MARKET ACCESS STRATEGY
4.2.2.4
AI-POWERED CLINICAL DEVELOPMENT AND DECENTRALIZED TRIAL MODELS
4.2.3
CHALLENGES
4.2.3.1
PATIENT RETENTION
4.2.3.2
CYBERSECURITY OR INTELLECTUAL PROPERTY CHALLENGES
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Emerging modalities and in silico trials redefine competitive dynamics and investment strategies in CRO services.
81
5.1
MARKET TRENDS
5.1.1
INTEGRATION OF HEOR AND RWE INTO CLINICAL TRIAL DESIGN
5.1.2
IN SILICO TRIALS
5.1.3
SPECIALIZED BIOANALYTICS FOR EMERGING MODALITIES (CGT)
5.2
PORTER’S FIVE FORCES ANALYSIS
5.2.1
THREAT OF NEW ENTRANTS
5.2.2
THREAT OF SUBSTITUTES
5.2.3
BARGAINING POWER OF BUYERS
5.2.4
BARGAINING POWER OF SUPPLIERS
5.2.5
INTENSITY OF COMPETITIVE RIVALRY
5.3
MACROECONOMIC OUTLOOK
5.3.1
INTRODUCTION
5.3.2
GDP TRENDS AND FORECAST
5.3.3
TRENDS IN GLOBAL CRO SERVICES MARKET
5.4
VALUE CHAIN ANALYSIS
5.5
ECOSYSTEM ANALYSIS
5.6
PRICING ANALYSIS
5.6.1
INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025
5.6.2
INDICATIVE PRICING ANALYSIS, BY PHASE, 2025
5.6.3
INDICATIVE PRICING ANALYSIS, BY REGION, 2025
5.7
KEY CONFERENCES & EVENTS, 2026–2027
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9
INVESTMENT AND FUNDING SCENARIO
5.10
IMPACT OF 2025 US TARIFFS—CRO SERVICES MARKET
5.10.1
INTRODUCTION
5.10.2
KEY TARIFF RATES
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON COUNTRIES/REGIONS
5.10.4.1
NORTH AMERICA
5.10.4.1.1
US
5.10.4.2
EUROPE
5.10.4.3
ASIA PACIFIC
5.10.5
IMPACT ON END-USE INDUSTRIES
5.10.5.1
PHARMACEUTICAL & BIOTECH COMPANIES
5.10.5.2
MEDICAL DEVICE COMPANIES
5.10.5.3
ACADEMIC INSTITUTES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations revolutionize clinical trials, enhancing efficiency, data accuracy, and drug development strategies.
97
6.1
KEY TECHNOLOGIES
6.1.1
AI-INTEGRATED CLINICAL TRIAL MANAGEMENT SYSTEM (CTMS) & ELECTRONIC TRIAL MASTER FILE (ETMF) PLATFORMS
6.1.2
RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT (RTSM)
6.1.3
ELECTRONIC DATA CAPTURE (EDC) SYSTEM
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
DIGITAL BIOMARKERS, WEARABLES & ELECTRONIC PATIENT-REPORTED OUTCOME (EPRO) TOOLS
6.2.2
MODEL-INFORMED DRUG DEVELOPMENT (MIDD)
6.2.3
DATA MANAGEMENT AND INFORMATICS TECHNOLOGIES
6.2.4
REAL-WORLD EVIDENCE (RWE) & REAL-WORLD DATA (RWD) PLATFORMS
6.3
ADJACENT TECHNOLOGIES
6.3.1
CLINICAL TRIAL SIMULATION TOOLS
6.4
TECHNOLOGY/SERVICE ROADMAP
6.5
FUTURE APPLICATIONS
6.6
IMPACT OF AI/GEN AI ON CRO SERVICES MARKET
6.6.1
INTRODUCTION
6.6.2
MARKET POTENTIAL ACROSS DRUG DEVELOPMENT STAGES
6.6.3
AI USE CASES
6.6.4
FUTURE OF GENERATIVE AI IN DRUG DEVELOPMENT ECOSYSTEM
7
REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
Navigate global regulatory nuances and sustainability benchmarks for strategic compliance and eco-leadership.
104
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
7.1.2.1
NORTH AMERICA
7.1.2.2
EUROPE
7.1.2.3
ASIA PACIFIC
7.1.2.4
REST OF THE WORLD
7.1.3
CERTIFICATIONS, LABELING, & ECO-STANDARDS
7.1.4
REGULATORY ANALYSIS
7.1.5
REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES
7.2
SUSTAINABILITY INITIATIVES
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Understand how stakeholder dynamics and unmet needs shape CRO service purchasing decisions.
115
8.1
DECISION-MAKING PROCESS
8.2
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2
BUYING CRITERIA
8.3
CUSTOMER LANDSCAPE
8.3.1
BUDGET ALLOCATION TREND
8.3.2
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5
MARKET PROFITABILITY
9
CRO SERVICES MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 163 Data Tables
120
9.1
INTRODUCTION
9.2
CLINICAL RESEARCH SERVICES
9.2.1
PHASE III
9.2.1.1
LARGE-SCALE TESTING ABILITY TO ASSESS EFFICACY AND SAFETY OF DRUGS TO AID GROWTH
9.2.2
PHASE II
9.2.2.1
GROWING NUMBER OF PIPELINE PRODUCTS IN PHASE II STUDIES TO DRIVE MARKET
9.2.3
PHASE I
9.2.3.1
ROBUST PIPELINE OF PHARMACEUTICAL AND BIOPHARMACEUTICAL PRODUCTS TO SUPPORT GROWTH
9.2.4
PHASE IV
9.2.4.1
STRINGENT GLOBAL REGULATIONS FOR DRUG SAFETY MONITORING TO SPUR GROWTH
9.3
EARLY-PHASE DEVELOPMENT SERVICES
9.3.1
CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES
9.3.1.1
GROWING NEED TO MEET REGULATORY NORMS FOR DRUGS TO FUEL MARKET
9.3.2
PRECLINICAL SERVICES
9.3.2.1
PHARMACOKINETICS/PHARMACODYNAMICS
9.3.2.1.1
RISE IN OUTSOURCING SERVICES BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES TO PROMOTE GROWTH
9.3.2.2
TOXICOLOGY TESTING
9.3.2.2.1
NEED TO PREVENT LATE-STAGE FAILURES TO CONTRIBUTE TO GROWTH
9.3.2.3
OTHER PRECLINICAL SERVICES
9.3.3
DISCOVERY STUDIES
9.3.3.1
INCREASING RELIANCE ON CRO SERVICES FOR TARGET IDENTIFICATION AND VALIDATION TO EXPEDITE GROWTH
9.4
LABORATORY SERVICES
9.4.1
ANALYTICAL TESTING
9.4.1.1
PHYSICAL CHARACTERIZATION
9.4.1.1.1
ABILITY TO MINIMIZE PRODUCT FAILURE IN LATE-PHASE DEVELOPMENT TO FAVOR GROWTH
9.4.1.2
RAW MATERIAL TESTING
9.4.1.2.1
NEED TO MAINTAIN QUALITY OF FINISHED PRODUCT TO FACILITATE GROWTH
9.4.1.3
BATCH-RELEASE TESTING
9.4.1.3.1
NEED TO MAINTAIN BATCH-TO-BATCH CONSISTENCY OF PHARMACEUTICAL DOSAGE FORMS TO ADVANCE GROWTH
9.4.1.4
STABILITY TESTING
9.4.1.4.1
ABILITY TO ESTABLISH DRUG COMPATIBILITY AND FORMULATION DEVELOPMENT TO AID GROWTH
9.4.1.5
OTHER ANALYTICAL TESTING SERVICES
9.4.2
BIOANALYTICAL TESTING
9.4.2.1
INCREASING OUTSOURCING OF R&D ACTIVITIES TO ACCELERATE GROWTH
9.5
CONSULTING SERVICES
9.5.1
GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER REGULATORY APPROVALS TO BOOST MARKET
9.6
DATA MANAGEMENT SERVICES
9.6.1
NEED TO TRACK PROGRESS OF EARLY DRUG DEVELOPMENT TO AUGMENT GROWTH
10
CRO SERVICES MARKET, BY DELIVERY MODEL
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
191
10.1
INTRODUCTION
10.2
FULL-SERVICE OUTSOURCING (FSO) MODEL
10.2.1
RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
10.3
FUNCTIONAL SERVICE PROVIDER (FSP) MODEL
10.3.1
GROWING ADOPTION OF FSP SERVICES BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH
10.4
HYBRID MODEL
10.4.1
HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH
11
CRO SERVICES MARKET, BY MODALITY
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 87 Data Tables
201
11.1
INTRODUCTION
11.2
SMALL MOLECULES
11.2.1
ONGOING SURGE IN PHARMACEUTICAL R&D INVESTMENTS TO SUPPORT GROWTH
11.3
BIOLOGICS
11.3.1
MONOCLONAL ANTIBODIES
11.3.1.1
SURGING DEMAND FOR TARGETED THERAPIES ACROSS ONCOLOGY, AUTOIMMUNE DISORDERS, AND INFECTIOUS DISEASES TO DRIVE MARKET
11.3.2
CELL & GENE THERAPY
11.3.2.1
ROBUST PIPELINE AND R&D INITIATIVES TO DRIVE MARKET
11.3.3
OTHER BIOLOGICS
11.4
MEDICAL DEVICES
11.4.1
RAPID INNOVATIONS IN DIAGNOSTICS, IMPLANTABLES, AND DIGITAL HEALTH TECHNOLOGIES TO FOSTER GROWTH
11.5
BIOSIMILARS
11.5.1
MONOCLONAL ANTIBODY BIOSIMILARS
11.5.1.1
RISING DEMAND FOR AFFORDABLE THERAPEUTIC OPTIONS TO SUPPORT GROWTH
11.5.2
INSULIN
11.5.2.1
INCREASING PATENT EXPIRATIONS TO CONTRIBUTE TO GROWTH
11.5.3
COLONY-STIMULATING FACTORS
11.5.3.1
INCREASING USE OF COLONY-STIMULATING FACTOR DURING POST-CHEMOTHERAPY TO AID GROWTH
11.5.4
ERYTHROPOIETIN
11.5.4.1
ESSENTIAL ROLE OF ERYTHROPOIETIN IN TREATING ANEMIA TO STIMULATE GROWTH
11.5.5
OTHER BIOSIMILARS
12
CRO SERVICES MARKET, BY THERAPEUTIC AREA
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 144 Data Tables
240
12.1
INTRODUCTION
12.2
ONCOLOGY
12.2.1
GROWING INCIDENCE OF CANCER TO DRIVE MARKET
12.2.2
BREAST CANCER
12.2.2.1
INCREASING CASES AND HIGH SPENDING ON TREATING BREAST CANCER TO SUPPORT GROWTH
12.2.3
LUNG CANCER
12.2.3.1
INCREASING FOCUS ON DEVELOPING DRUGS AGAINST LUNG CANCER TO FOSTER GROWTH
12.2.4
COLORECTAL CANCER
12.2.4.1
INCREASING DRUG DISCOVERY AND DEVELOPMENT EFFORTS AGAINST COLORECTAL CANCER TO AID GROWTH
12.2.5
PROSTATE CANCER
12.2.5.1
GROWING CLINICAL PIPELINE TO PROPEL MARKET
12.2.6
OTHER CANCERS
12.3
INFECTIOUS DISEASES
12.3.1
INCREASING INCIDENCE OF CHRONIC INFECTIONS TO SUPPORT GROWTH
12.4
CARDIOVASCULAR SYSTEM DISORDERS
12.4.1
HIGH MORTALITY RATES OF CARDIOVASCULAR DISEASES TO FUEL MARKET
12.5
NEUROLOGY
12.5.1
GROWING INVESTMENTS IN NEUROLOGICAL DISORDER RESEARCH TO DRIVE MARKET
12.6
VACCINES
12.6.1
INCREASING FOCUS ON VACCINE DEVELOPMENT TO SPUR GROWTH
12.7
METABOLIC DISORDERS/ENDOCRINOLOGY
12.7.1
INCREASING GLOBAL DIABETES AND OBESITY POPULATION TO PROMOTE GROWTH
12.8
IMMUNOLOGICAL DISORDERS
12.8.1
GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET
12.9
PSYCHIATRY
12.9.1
RISING CASES OF PSYCHIATRIC DISORDERS AND DEPRESSION TO SUSTAIN GROWTH
12.10
RESPIRATORY DISORDERS
12.10.1
RISING INCIDENCE OF CHRONIC RESPIRATORY DISEASE TO FOSTER GROWTH
12.11
DERMATOLOGY
12.11.1
GROWING FOCUS ON DRUG DEVELOPMENT AGAINST VARIOUS SKIN CONDITIONS TO DRIVE MARKET
12.12
OPHTHALMOLOGY
12.12.1
GROWTH IN NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH
12.13
GASTROINTESTINAL DISEASES
12.13.1
RAPID LIFESTYLE AND DIETARY CHANGES TO AMPLIFY GROWTH
12.14
GENITOURINARY & WOMEN’S HEALTH
12.14.1
RISING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS AND TREATMENT TO BOLSTER MARKET
12.15
HEMATOLOGY
12.15.1
INCREASING DRUG APPROVALS FOR DRUGS AGAINST NON-MALIGNANT HEMATOLOGICAL CONDITIONS TO SUPPORT GROWTH
12.16
OTHER THERAPEUTIC AREAS
13
CRO SERVICES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 37 Data Tables
303
13.1
INTRODUCTION
13.2
PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
13.2.1
INCREASING OUTSOURCING AND PARTNERSHIPS TO ACCELERATE GROWTH
13.2.2
LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
13.2.2.1
DEMAND FOR THERAPEUTIC EXPERTISE AND GLOBAL REACH TO AID OUTSOURCING TO CROS
13.2.3
SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
13.2.3.1
DEMAND IS DRIVEN BY NEED TO CONTROL FIXED COSTS, ACCESS GLOBAL DEVELOPMENT EXPERTISE, AND ACCELERATE TIMELINES
13.3
MEDICAL DEVICE COMPANIES
13.3.1
INCREASING GROWTH INITIATIVES BY MEDTECH CROS TO DRIVE MARKET
13.4
ACADEMIC INSTITUTES
13.4.1
CONSISTENT COLLABORATIONS BETWEEN CROS AND ACADEMIA TO INTENSIFY GROWTH
14
CRO SERVICES MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 18 Countries | 399 Data Tables.
322
14.1
INTRODUCTION
14.2
NORTH AMERICA
14.2.1
US
14.2.1.1
INCREASING INCIDENCE OF ONCOLOGY INDICATIONS TO ACCELERATE GROWTH
14.2.2
CANADA
14.2.2.1
FAVORABLE GOVERNMENT INITIATIVES AND HIGH INVESTMENTS TO SUPPORT GROWTH
14.3
EUROPE
14.3.1
GERMANY
14.3.1.1
PRESENCE OF STRONG PHARMACEUTICAL AND BIOTECHNOLOGY R&D INFRASTRUCTURE TO SPUR GROWTH
14.3.2
UK
14.3.2.1
RISING PHARMACEUTICAL R&D EXPENDITURE TO EXPEDITE GROWTH
14.3.3
FRANCE
14.3.3.1
INCREASING TECHNOLOGICAL ADVANCEMENTS AND FASTER DRUG DISCOVERY AND DEVELOPMENT INITIATIVES TO AID GROWTH
14.3.4
ITALY
14.3.4.1
SHORT TIMELINE FOR DRUG APPROVALS TO ENCOURAGE GROWTH
14.3.5
SPAIN
14.3.5.1
GROWING INVESTMENT IN PHARMACEUTICAL INDUSTRY TO BOOST MARKET
14.3.6
REST OF EUROPE
14.4
ASIA PACIFIC
14.4.1
CHINA
14.4.1.1
CONTINUED EFFORTS ON IMPROVING THE LEVEL OF DRUG SAFETY AND SUPPLY TO SPUR GROWTH
14.4.2
INDIA
14.4.2.1
LARGE POOL OF PATIENTS AND PRESENCE OF HIGHLY SKILLED MEDICAL PROFESSIONALS TO AUGMENT GROWTH
14.4.3
JAPAN
14.4.3.1
GROWING DRUG DEVELOPMENT ACTIVITY TO PROPEL MARKET
14.4.4
AUSTRALIA
14.4.4.1
GROWING FOCUS ON FUNDING OPPORTUNITIES TO PROPEL MARKET
14.4.5
SOUTH KOREA
14.4.5.1
EMERGING CLINICAL RESEARCH HUB TO SUSTAIN GROWTH
14.4.6
REST OF ASIA PACIFIC
14.5
LATIN AMERICA
14.5.1
BRAZIL
14.5.1.1
GROWING FOCUS ON ENHANCING PHARMACEUTICAL RESEARCH AND PRODUCTION TO FUEL MARKET
14.5.2
MEXICO
14.5.2.1
INCREASING INVESTMENTS IN PHARMA R&D TO PROMOTE GROWTH
14.5.3
REST OF LATIN AMERICA
14.6
MIDDLE EAST
14.6.1
GCC COUNTRIES
14.6.1.1
KINGDOM OF SAUDI ARABIA (KSA)
14.6.1.1.1
EXPANDING CLINICAL TRIALS ECOSYSTEM TO CONTRIBUTE TO GROWTH
14.6.1.2
UNITED ARAB EMIRATES (UAE)
14.6.1.2.1
GROWING CLINICAL TRIALS ACTIVITY TO DRIVE MARKET
14.6.1.3
REST OF GCC COUNTRIES
14.6.2
REST OF MIDDLE EAST
14.7
AFRICA
14.7.1
BOOMING PHARMACEUTICAL INDUSTRY TO FACILITATE GROWTH
15
COMPETITIVE LANDSCAPE
Discover key player strategies and market dynamics shaping the CRO services competitive landscape.
487
15.1
INTRODUCTION
15.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRO SERVICES MARKET, JANUARY 2023-MARCH 2026
15.3
REVENUE ANALYSIS, 2021–2025
15.4
MARKET SHARE ANALYSIS, 2025
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1
STARS
15.5.2
EMERGING LEADERS
15.5.3
PERVASIVE PLAYERS
15.5.4
PARTICIPANTS
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1
COMPANY FOOTPRINT
15.5.5.2
REGION FOOTPRINT
15.5.5.3
TYPE FOOTPRINT
15.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1
PROGRESSIVE COMPANIES
15.6.2
RESPONSIVE COMPANIES
15.6.3
DYNAMIC COMPANIES
15.6.4
STARTING BLOCKS
15.6.5
COMPETITIVE BENCHMARKING
15.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.6.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
15.7
COMPANY VALUATION & FINANCIAL METRICS
15.7.1
FINANCIAL METRICS
15.7.2
COMPANY VALUATION
15.8
SERVICE COMPARISON
15.9
COMPETITIVE SCENARIO
15.9.1
SERVICE LAUNCHES & APPROVALS
15.9.2
DEALS
15.9.3
EXPANSIONS
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
506
16.1
KEY PLAYERS
16.1.1
IQVIA INC.
16.1.1.1
BUSINESS OVERVIEW
16.1.1.2
SERVICES/SOLUTIONS OFFERED
16.1.1.3
RECENT DEVELOPMENTS
16.1.1.3.1
PRODUCT & SERVICE LAUNCHES
16.1.1.3.2
DEALS
16.1.1.4
MNM VIEW
16.1.1.4.1
KEY STRENGTHS/RIGHT TO WIN
16.1.1.4.2
STRATEGIC CHOICES MADE
16.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
16.1.2
ICON PLC
16.1.3
THERMO FISHER SCIENTIFIC INC.
16.1.4
LABORATORY CORPORATION OF AMERICA HOLDINGS
16.1.5
FORTREA, INC.
16.1.6
SYNEOS HEALTH
16.1.7
WUXI APPTEC
16.1.8
CHARLES RIVER LABORATORIES
16.1.9
PAREXEL INTERNATIONAL CORPORATION
16.1.10
PHARMARON
16.1.11
MEDPACE
16.1.12
SGS SA
16.1.13
FRONTAGE LABS
16.1.14
EUROFINS SCIENTIFIC
16.1.15
TIGERMED
16.1.16
PSI CRO AG
16.1.17
BIOAGILE
16.1.18
FIRMA CLINICAL RESEARCH
16.1.19
ACCULAB LIFE SCIENCES
16.1.20
NOVOTECH
16.1.21
LINICAL
16.1.22
ADVANCED CLINICAL
16.2
OTHER PLAYERS
16.2.1
ALLUCENT
16.2.2
EMVENIO
16.2.3
GUIRES INC. (PEPGRA HEALTHCARE PVT. LTD.)
16.2.4
WORLDWIDE CLINICAL TRIALS
16.2.5
CTI CLINICAL TRIAL & CONSULTING
17
RESEARCH METHODOLOGY
598
17.1
RESEARCH APPROACH
17.1.1
SECONDARY DATA
17.1.1.1
KEY SOURCES OF SECONDARY DATA
17.1.1.2
KEY OBJECTIVES OF SECONDARY RESEARCH
17.1.2
PRIMARY DATA
17.1.2.1
BREAKDOWN OF PRIMARIES
17.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
17.2
MARKET ESTIMATION METHODOLOGY
17.2.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
17.2.2
MNM REPOSITORY ANALYSIS AND PRIMARY RESEARCH
17.2.3
SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
17.3
GROWTH RATE PROJECTIONS
17.4
DATA TRIANGULATION
17.5
RESEARCH ASSUMPTIONS
17.6
RESEARCH LIMITATIONS
17.7
RISK ANALYSIS
18
APPENDIX
611
18.1
DISCUSSION GUIDE
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3
CUSTOMIZATION OPTIONS
18.4
RELATED REPORTS
18.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
IMPACT ANALYSIS: CRO SERVICES MARKET
TABLE 2
PORTER’S FIVE FORCES ANALYSIS: CRO SERVICES MARKET
TABLE 3
CRO SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 4
INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025 (USD)
TABLE 5
INDICATIVE PRICING ANALYSIS, BY SERVICE TYPE, 2025 (USD MILLION)
TABLE 6
INDICATIVE PRICING ANALYSIS (PER STUDY), BY REGION, 2025 (USD MILLION)
TABLE 7
DETAILED LIST OF KEY CONFERENCES & EVENTS, 2026–2027
TABLE 8
BEST PRACTICES FOLLOWED BY COMPANIES IN CRO SERVICES MARKET
TABLE 9
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES, BY MODALITY
TABLE 14
BUYING CRITERIA FOR CRO SERVICES ACROSS END USERS
TABLE 15
CRO SERVICES: ADOPTION BARRIERS & INTERNAL FRICTION
TABLE 16
CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 17
CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS
TABLE 18
CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION)
TABLE 19
CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 20
NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 21
EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 22
ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 23
LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 24
MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 25
GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 26
CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY REGION, 2024–2031 (USD MILLION)
TABLE 27
NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 28
EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 29
ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30
LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31
MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY REGION, 2024–2031 (USD MILLION)
TABLE 32
GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33
CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY REGION, 2024–2031 (USD MILLION)
TABLE 34
NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35
EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36
ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37
LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38
MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY REGION, 2024–2031 (USD MILLION)
TABLE 39
GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40
CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY REGION, 2024–2031 (USD MILLION)
TABLE 41
NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42
EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43
ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44
LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45
MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY REGION, 2024–2031 (USD MILLION)
TABLE 46
GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47
CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY REGION, 2024–2031 (USD MILLION)
TABLE 48
NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49
EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50
ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51
LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52
MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY REGION, 2024–2031 (USD MILLION)
TABLE 53
GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54
EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 55
EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 56
NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57
EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58
ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59
LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60
MIDDLE EAST: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61
GCC COUNTRIES: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62
CMC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 63
NORTH AMERICA: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64
EUROPE: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65
ASIA PACIFIC: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66
LATIN AMERICA: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67
MIDDLE EAST: CMC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 68
GCC COUNTRIES: CMC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69
PRECLINICAL SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 70
PRECLINICAL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 71
NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72
EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73
ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74
LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75
MIDDLE EAST: PRECLINICAL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 76
GCC COUNTRIES: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77
PK/PD SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 78
NORTH AMERICA: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79
EUROPE: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80
ASIA PACIFIC: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81
LATIN AMERICA: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82
MIDDLE EAST: PK/PD SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 83
GCC COUNTRIES: PK/PD SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84
TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 85
NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86
EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87
ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88
LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89
MIDDLE EAST: TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 90
GCC COUNTRIES: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91
OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 92
NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93
EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94
ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95
LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96
MIDDLE EAST: OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 97
GCC COUNTRIES: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98
CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 99
NORTH AMERICA: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100
EUROPE: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101
ASIA PACIFIC: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102
LATIN AMERICA: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103
MIDDLE EAST: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 104
GCC COUNTRIES: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105
LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 106
LABORATORY SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 107
LABORATORY SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 108
NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109
EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110
ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111
LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112
MIDDLE EAST: LABORATORY SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 113
GCC COUNTRIES: LABORATORY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114
ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 115
ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 116
NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117
EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118
ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119
LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120
MIDDLE EAST: ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 121
GCC COUNTRIES: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122
CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 123
NORTH AMERICA: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124
EUROPE: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125
ASIA PACIFIC: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126
LATIN AMERICA: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127
MIDDLE EAST: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 128
GCC COUNTRIES: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129
CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 130
NORTH AMERICA: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131
EUROPE: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132
ASIA PACIFIC: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133
LATIN AMERICA: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134
MIDDLE EAST: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 135
GCC COUNTRIES: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136
CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 137
NORTH AMERICA: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138
EUROPE: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139
ASIA PACIFIC: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140
LATIN AMERICA: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141
MIDDLE EAST: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 142
GCC COUNTRIES: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143
CRO SERVICES MARKET FOR STABILITY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 144
NORTH AMERICA: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145
EUROPE: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146
ASIA PACIFIC: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147
LATIN AMERICA: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148
MIDDLE EAST: CRO SERVICES MARKET FOR STABILITY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 149
GCC COUNTRIES: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150
OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 151
NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152
EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153
ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154
LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155
MIDDLE EAST: OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 156
GCC COUNTRIES: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157
BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 158
NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159
EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160
ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161
LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162
MIDDLE EAST: BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 163
GCC COUNTRIES: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164
CONSULTING SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 165
CONSULTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 166
NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167
EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168
ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169
LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170
MIDDLE EAST: CONSULTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 171
GCC COUNTRIES: CONSULTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172
DATA MANAGEMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 173
NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174
EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175
ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176
LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177
MIDDLE EAST: DATA MANAGEMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 178
GCC COUNTRIES: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179
CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 180
CRO SERVICES MARKET FOR FSO MODEL, BY REGION, 2024–2031 (USD MILLION)
TABLE 181
NORTH AMERICA: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182
EUROPE: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183
ASIA PACIFIC: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184
LATIN AMERICA: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 185
MIDDLE EAST: CRO SERVICES MARKET FOR FSO MODEL, BY REGION, 2024–2031 (USD MILLION)
TABLE 186
GCC COUNTRIES: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187
CRO SERVICES MARKET FOR FSP MODEL, BY REGION, 2024–2031 (USD MILLION)
TABLE 188
NORTH AMERICA: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189
EUROPE: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190
ASIA PACIFIC: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191
LATIN AMERICA: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192
MIDDLE EAST: CRO SERVICES MARKET FOR FSP MODEL, BY REGION, 2024–2031 (USD MILLION)
TABLE 193
GCC COUNTRIES: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194
CRO SERVICES MARKET FOR HYBRID MODEL, BY REGION, 2024–2031 (USD MILLION)
TABLE 195
NORTH AMERICA: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196
EUROPE: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197
ASIA PACIFIC: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198
LATIN AMERICA: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199
MIDDLE EAST: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200
GCC COUNTRIES: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201
CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 202
CRO SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2031 (USD MILLION)
TABLE 203
NORTH AMERICA: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204
EUROPE: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205
ASIA PACIFIC: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206
LATIN AMERICA: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207
MIDDLE EAST: CRO SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2031 (USD MILLION)
TABLE 208
GCC COUNTRIES: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209
CRO SERVICES MARKET FOR BIOLOGICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 210
NORTH AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211
EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212
ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213
LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214
MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 215
GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216
CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 217
CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 218
NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219
EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220
ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 221
LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222
MIDDLE EAST: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 223
GCC COUNTRIES: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224
CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 225
NORTH AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226
EUROPE: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227
ASIA PACIFIC: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228
LATIN AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 229
MIDDLE EAST: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2024–2031 (USD MILLION)
TABLE 230
GCC COUNTRIES: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231
CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 232
NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233
EUROPE: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234
ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235
LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236
MIDDLE EAST: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 237
GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238
CRO SERVICES MARKET FOR MEDICAL DEVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 239
NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240
EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241
ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242
LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 243
MIDDLE EAST: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 244
GCC COUNTRIES: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245
CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 246
CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION)
TABLE 247
NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248
EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249
ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 250
LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251
MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION)
TABLE 252
GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253
CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION)
TABLE 254
NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255
EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256
ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257
LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258
MIDDLE EAST: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION)
TABLE 259
GCC COUNTRIES: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260
CRO SERVICES MARKET FOR INSULIN, BY REGION, 2024–2031 (USD MILLION)
TABLE 261
NORTH AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262
EUROPE: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263
ASIA PACIFIC: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264
LATIN AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265
MIDDLE EAST: CRO SERVICES MARKET FOR INSULIN, BY REGION, 2024–2031 (USD MILLION)
TABLE 266
GCC COUNTRIES: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267
CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 268
NORTH AMERICA: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269
EUROPE: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270
ASIA PACIFIC: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 271
LATIN AMERICA: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272
MIDDLE EAST: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY REGION, 2024–2031 (USD MILLION)
TABLE 273
GCC COUNTRIES: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274
CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION, 2024–2031 (USD MILLION)
TABLE 275
NORTH AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276
EUROPE: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277
ASIA PACIFIC: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 278
LATIN AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279
MIDDLE EAST: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION, 2024–2031 (USD MILLION)
TABLE 280
GCC COUNTRIES: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 281
CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION)
TABLE 282
NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283
EUROPE: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284
ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285
LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286
MIDDLE EAST: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION, 2024–2031 (USD MILLION)
TABLE 287
GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 288
CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 289
NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040
TABLE 290
CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 291
CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 292
NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 293
EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 294
ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 295
LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 296
MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 297
GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298
CRO SERVICES MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 299
NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 300
EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 301
ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 302
LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 303
MIDDLE EAST: CRO SERVICES MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 304
GCC COUNTRIES: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305
CRO SERVICES MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 306
NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 307
EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 308
ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 309
LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 310
MIDDLE EAST: CRO SERVICES MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 311
GCC COUNTRIES: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 312
CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 313
NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 314
EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 315
ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 316
LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 317
MIDDLE EAST: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 318
GCC COUNTRIES: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 319
CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 320
NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 321
EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 322
ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 323
LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 324
MIDDLE EAST: CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION)
TABLE 325
GCC COUNTRIES: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 326
NUMBER OF DRUGS IN R&D PIPELINE FOR OTHER CANCERS, 2023–2025
TABLE 327
CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 328
NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 329
EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 330
ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 331
LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 332
MIDDLE EAST: CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 333
GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 334
CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 335
NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 336
EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 337
ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 338
LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 339
MIDDLE EAST: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 340
GCC COUNTRIES: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 341
CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 342
NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 343
EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 344
ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 345
LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 346
MIDDLE EAST: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 347
GCC COUNTRIES: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 348
CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 349
NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 350
EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 351
ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 352
LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 353
MIDDLE EAST: CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 354
GCC COUNTRIES: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 355
CRO SERVICES MARKET FOR VACCINES, BY REGION, 2024–2031 (USD MILLION)
TABLE 356
NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 357
EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 358
ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 359
LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 360
MIDDLE EAST: CRO SERVICES MARKET FOR VACCINES, BY REGION, 2024–2031 (USD MILLION)
TABLE 361
GCC COUNTRIES: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 362
CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 363
NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 364
EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 365
ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 366
LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 367
MIDDLE EAST: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 368
GCC COUNTRIES: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 369
CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 370
NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 371
EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 372
ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 373
LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 374
MIDDLE EAST: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 375
GCC COUNTRIES: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 376
CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 377
NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 378
EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 379
ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 380
LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 381
MIDDLE EAST: CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 382
GCC COUNTRIES: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 383
CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 384
NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 385
EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 386
ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 387
LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 388
MIDDLE EAST: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 389
GCC COUNTRIES: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 390
CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 391
NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 392
EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 393
ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 394
LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 395
MIDDLE EAST: CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 396
GCC COUNTRIES: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 397
CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 398
NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 399
EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 400
ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 401
LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 402
MIDDLE EAST: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 403
GCC COUNTRIES: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 404
CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 405
NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 406
EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 407
ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 408
LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 409
MIDDLE EAST: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 410
GCC COUNTRIES: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 411
CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2024–2031 (USD MILLION)
TABLE 412
NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 413
EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 414
ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 415
LATIN AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 416
MIDDLE EAST: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2024–2031 (USD MILLION)
TABLE 417
GCC COUNTRIES: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 418
CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 419
NORTH AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 420
EUROPE: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 421
ASIA PACIFIC: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 422
LATIN AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 423
MIDDLE EAST: CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2024–2031 (USD MILLION)
TABLE 424
GCC COUNTRIES: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 425
CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION)
TABLE 426
NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 427
EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 428
ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 429
LATIN AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 430
MIDDLE EAST: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION)
TABLE 431
GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 432
CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 433
CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 434
CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 435
NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 436
EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 437
ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 438
LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 439
MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 440
GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 441
CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 442
NORTH AMERICA: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 443
EUROPE: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 444
ASIA PACIFIC: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 445
LATIN AMERICA: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 446
MIDDLE EAST: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 447
GCC COUNTRIES: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 448
CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 449
NORTH AMERICA: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 450
EUROPE: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 451
ASIA PACIFIC: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 452
LATIN AMERICA: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 453
MIDDLE EAST: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 454
GCC COUNTRIES: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 455
CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 456
NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 457
EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 458
ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 459
LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 460
MIDDLE EAST: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 461
GCC COUNTRIES: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 462
CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 463
NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 464
EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 465
ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 466
LATIN AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 467
MIDDLE EAST: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 468
GCC COUNTRIES: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 469
CRO SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 470
NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 471
NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 472
NORTH AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 473
NORTH AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 474
NORTH AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 475
NORTH AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 476
NORTH AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 477
NORTH AMERICA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 478
NORTH AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 479
NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 480
NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 481
NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 482
NORTH AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 483
NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 484
NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 485
US: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 486
US: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 487
US: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 488
US: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 489
US: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 490
US: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 491
US: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 492
US: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 493
US: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 494
US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 495
US: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 496
US: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 497
US: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 498
US: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 499
CANADA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 500
CANADA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 501
CANADA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 502
CANADA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 503
CANADA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 504
CANADA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 505
CANADA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 506
CANADA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 507
CANADA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 508
CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 509
CANADA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 510
CANADA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 511
CANADA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 512
CANADA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 513
EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 514
EUROPE: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 515
EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 516
EUROPE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 517
EUROPE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 518
EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 519
EUROPE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 520
EUROPE: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 521
EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 522
EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 523
EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 524
EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 525
EUROPE: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 526
EUROPE: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 527
EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 528
GERMANY: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 529
GERMANY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 530
GERMANY: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 531
GERMANY: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 532
GERMANY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 533
GERMANY: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 534
GERMANY: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 535
GERMANY: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 536
GERMANY: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 537
GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 538
GERMANY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 539
GERMANY: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 540
GERMANY: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 541
GERMANY: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 542
UK: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 543
UK: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 544
UK: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 545
UK: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 546
UK: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 547
UK: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 548
UK: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 549
UK: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 550
UK: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 551
UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 552
UK: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 553
UK: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 554
UK: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 555
UK: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 556
FRANCE: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 557
FRANCE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 558
FRANCE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 559
FRANCE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 560
FRANCE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 561
FRANCE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 562
FRANCE: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 563
FRANCE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 564
FRANCE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 565
FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 566
FRANCE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 567
FRANCE: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 568
FRANCE: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 569
FRANCE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 570
ITALY: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 571
ITALY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 572
ITALY: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 573
ITALY: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 574
ITALY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 575
ITALY: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 576
ITALY: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 577
ITALY: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 578
ITALY: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 579
ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 580
ITALY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 581
ITALY: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 582
ITALY: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 583
ITALY: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 584
SPAIN: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 585
SPAIN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 586
SPAIN: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 587
SPAIN: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 588
SPAIN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 589
SPAIN: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 590
SPAIN: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 591
SPAIN: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 592
SPAIN: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 593
SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 594
SPAIN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 595
SPAIN: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 596
SPAIN: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 597
SPAIN: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 598
REST OF EUROPE: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 599
REST OF EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 600
REST OF EUROPE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 601
REST OF EUROPE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 602
REST OF EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 603
REST OF EUROPE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 604
REST OF EUROPE: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 605
REST OF EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 606
REST OF EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 607
REST OF EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 608
REST OF EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 609
REST OF EUROPE: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 610
REST OF EUROPE: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 611
REST OF EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 612
ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 613
ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 614
ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 615
ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 616
ASIA PACIFIC: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 617
ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 618
ASIA PACIFIC: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 619
ASIA PACIFIC: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 620
ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 621
ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 622
ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 623
ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 624
ASIA PACIFIC: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 625
ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 626
ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 627
CHINA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 628
CHINA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 629
CHINA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 630
CHINA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 631
CHINA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 632
CHINA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 633
CHINA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 634
CHINA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 635
CHINA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 636
CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 637
CHINA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 638
CHINA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 639
CHINA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 640
CHINA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 641
INDIA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 642
INDIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 643
INDIA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 644
INDIA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 645
INDIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 646
INDIA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 647
INDIA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 648
INDIA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 649
INDIA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 650
INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 651
INDIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 652
INDIA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 653
INDIA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 654
INDIA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 655
JAPAN: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 656
JAPAN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 657
JAPAN: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 658
JAPAN: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 659
JAPAN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 660
JAPAN: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 661
JAPAN: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 662
JAPAN: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 663
JAPAN: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 664
JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 665
JAPAN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 666
JAPAN: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 667
JAPAN: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 668
JAPAN: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 669
AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 670
AUSTRALIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 671
AUSTRALIA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 672
AUSTRALIA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 673
AUSTRALIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 674
AUSTRALIA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 675
AUSTRALIA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 676
AUSTRALIA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 677
AUSTRALIA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 678
AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 679
AUSTRALIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 680
AUSTRALIA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 681
AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 682
AUSTRALIA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 683
SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 684
SOUTH KOREA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 685
SOUTH KOREA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 686
SOUTH KOREA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 687
SOUTH KOREA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 688
SOUTH KOREA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 689
SOUTH KOREA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 690
SOUTH KOREA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 691
SOUTH KOREA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 692
SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 693
SOUTH KOREA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 694
SOUTH KOREA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 695
SOUTH KOREA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 696
SOUTH KOREA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 697
REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 698
REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 699
REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 700
REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 701
REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 702
REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 703
REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 704
REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 705
REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 706
REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 707
REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 708
REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 709
REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 710
REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 711
LATIN AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 712
LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 713
LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 714
LATIN AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 715
LATIN AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 716
LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 717
LATIN AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 718
LATIN AMERICA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 719
LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 720
LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 721
LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 722
LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 723
LATIN AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 724
LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 725
LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 726
BRAZIL: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 727
BRAZIL: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 728
BRAZIL: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 729
BRAZIL: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 730
BRAZIL: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 731
BRAZIL: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 732
BRAZIL: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 733
BRAZIL: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 734
BRAZIL: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 735
BRAZIL: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 736
BRAZIL: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 737
BRAZIL: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 738
BRAZIL: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 739
BRAZIL: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 740
MEXICO: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 741
MEXICO: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 742
MEXICO: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 743
MEXICO: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 744
MEXICO: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 745
MEXICO: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 746
MEXICO: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 747
MEXICO: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 748
MEXICO: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 749
MEXICO: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 750
MEXICO: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 751
MEXICO: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 752
MEXICO: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 753
MEXICO: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 754
REST OF LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 755
REST OF LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 756
REST OF LATIN AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 757
REST OF LATIN AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 758
REST OF LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 759
REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 760
REST OF LATIN AMERICA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 761
REST OF LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 762
REST OF LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 763
REST OF LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 764
REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 765
REST OF LATIN AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 766
REST OF LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 767
REST OF LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 768
MIDDLE EAST: CRO SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 769
MIDDLE EAST: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 770
MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 771
MIDDLE EAST: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 772
MIDDLE EAST: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 773
MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 774
MIDDLE EAST: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 775
MIDDLE EAST: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 776
MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 777
MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 778
MIDDLE EAST: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 779
MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 780
MIDDLE EAST: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 781
MIDDLE EAST: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 782
MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 783
GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 784
GCC COUNTRIES: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 785
GCC COUNTRIES: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 786
GCC COUNTRIES: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 787
GCC COUNTRIES: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 788
GCC COUNTRIES: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 789
GCC COUNTRIES: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 790
GCC COUNTRIES: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 791
GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 792
GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 793
GCC COUNTRIES: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 794
GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 795
GCC COUNTRIES: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 796
GCC COUNTRIES: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 797
GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 798
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 799
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 800
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 801
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 802
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 803
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 804
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 805
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 806
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 807
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 808
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 809
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 810
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 811
KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 812
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 813
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 814
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 815
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 816
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 817
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 818
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 819
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 820
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 821
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 822
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 823
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 824
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 825
UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 826
REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 827
REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 828
REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 829
REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 830
REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 831
REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 832
REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 833
REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 834
REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 835
REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 836
REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 837
REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 838
REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 839
REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 840
REST OF MIDDLE EAST: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 841
REST OF MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 842
REST OF MIDDLE EAST: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 843
REST OF MIDDLE EAST: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 844
REST OF MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 845
REST OF MIDDLE EAST: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 846
REST OF MIDDLE EAST: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 847
REST OF MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 848
REST OF MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 849
REST OF MIDDLE EAST: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 850
REST OF MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 851
REST OF MIDDLE EAST: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 852
REST OF MIDDLE EAST: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 853
REST OF MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 854
AFRICA: CRO SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 855
AFRICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024–2031 (USD MILLION)
TABLE 856
AFRICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 857
AFRICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 858
AFRICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 859
AFRICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 860
AFRICA: CRO SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 861
AFRICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 862
AFRICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 863
AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION)
TABLE 864
AFRICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION)
TABLE 865
AFRICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION)
TABLE 866
AFRICA: CRO SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 867
AFRICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 868
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CRO SERVICES MARKET, JANUARY 2023-MARCH 2026
TABLE 869
CRO SERVICES MARKET: DEGREE OF COMPETITION
TABLE 870
CRO SERVICES MARKET: REGION FOOTPRINT
TABLE 871
CRO SERVICES MARKET: TYPE FOOTPRINT
TABLE 872
CRO SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 873
CRO SERVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY TYPE AND REGION
TABLE 874
CRO SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 875
CRO SERVICES MARKET: DEALS, JANUARY 2023–MARCH 2026
TABLE 876
CRO SERVICES MARKET: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 877
IQVIA INC.: COMPANY OVERVIEW
TABLE 878
IQVIA INC.: SERVICES/SOLUTIONS OFFERED
TABLE 879
IQVIA INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 880
IQVIA INC.: DEALS, JANUARY 2023–MARCH 2026
TABLE 881
ICON PLC: COMPANY OVERVIEW
TABLE 882
ICON PLC.: SERVICES/SOLUTIONS OFFERED
TABLE 883
ICON PLC.: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 884
ICON PLC: DEALS, JANUARY 2023–MARCH 2026
TABLE 885
ICON PLC.: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 886
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 887
THERMO FISHER SCIENTIFIC INC.: SERVICES/SOLUTIONS OFFERED
TABLE 888
THERMO FISHER SCIENTIFIC, INC.: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 889
THERMO FISHER SCIENTIFIC, INC.: DEALS, JANUARY 2021–APRIL 2026
TABLE 890
THERMO FISHER SCIENTIFIC, INC.: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 891
LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
TABLE 892
LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES/SOLUTIONS OFFERED
TABLE 893
LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 894
LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS, JANUARY 2023–MARCH 2026
TABLE 895
LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 896
LABORATORY CORPORATION OF AMERICA HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026
TABLE 897
FORTREA, INC.: BUSINESS OVERVIEW
TABLE 898
FORTREA, INC.: SERVICES/SOLUTIONS OFFERED
TABLE 899
FORTREA, INC.: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 900
FORTREA, INC.: DEALS, JANUARY 2023–MARCH 2026
TABLE 901
FORTREA, INC.: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 902
FORTREA, INC.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026
TABLE 903
SYNEOS HEALTH: COMPANY OVERVIEW
TABLE 904
SYNEOS HEALTH: SERVICES/SOLUTIONS OFFERED
TABLE 905
SYNEOS HEALTH: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 906
SYNEOS HEALTH: DEALS, JANUARY 2023–MARCH 2026
TABLE 907
WUXI APPTEC: COMPANY OVERVIEW
TABLE 908
WUXI APPTEC: SERVICES/SOLUTIONS OFFERED
TABLE 909
WUXI APPTEC: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 910
WUXI APPTEC: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026
TABLE 911
CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
TABLE 912
CHARLES RIVER LABORATORIES: SERVICES/SOLUTIONS OFFERED
TABLE 913
CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023–MARCH 2026
TABLE 914
PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW
TABLE 915
PAREXEL INTERNATIONAL CORPORATION: SERVICES/SOLUTIONS OFFERED
TABLE 916
PAREXEL INTERNATIONAL CORPORATION: DEALS, JANUARY 2023–MARCH 2026
TABLE 917
PAREXEL INTERNATIONAL CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 918
PHARMARON: COMPANY OVERVIEW
TABLE 919
PHARMARON: SERVICES/SOLUTIONS OFFERED
TABLE 920
MEDPACE: COMPANY OVERVIEW
TABLE 921
MEDPACE: SERVICES/SOLUTIONS OFFERED
TABLE 922
SGS SA: COMPANY OVERVIEW
TABLE 923
SGS SA: SERVICES/SOLUTIONS OFFERED
TABLE 924
SGS SA: DEALS, JANUARY 2023–MARCH 2026
TABLE 925
FRONTAGE LABS: COMPANY OVERVIEW
TABLE 926
FRONTAGE LABS: SERVICES/SOLUTIONS OFFERED
TABLE 927
FRONTAGE LABS: DEALS, JANUARY 2023–MARCH 2026
TABLE 928
FRONTAGE LABS: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026
TABLE 929
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 930
EUROFINS SCIENTIFIC: SERVICES/SOLUTIONS OFFERED
TABLE 931
TIGERMED: COMPANY OVERVIEW
TABLE 932
TIGERMED: SERVICES OFFERED
TABLE 933
TIGERMED: PRODUCT/ SERVICE APPROVALS, JANUARY 2023–MARCH 2026
TABLE 934
TIGERMED: DEALS, JANUARY 2023–MARCH 2026
TABLE 935
PSI CRO AG: COMPANY OVERVIEW
TABLE 936
PSI CRO AG: SERVICES/SOLUTIONS OFFERED
TABLE 937
PSI CRO AG: SERVICE LAUNCHES, JANUARY 2023–MARCH 2026
TABLE 938
PSI CRO AG: DEALS, JANUARY 2023–MARCH 2026
TABLE 939
PSI CRO AG: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 940
BIOAGILE: COMPANY OVERVIEW
TABLE 941
BIOAGILE: SERVICES/SOLUTIONS OFFERED
TABLE 942
FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW
TABLE 943
FIRMA CLINICAL RESEARCH: SERVICES/SOLUTIONS OFFERED
TABLE 944
ACCULAB LIFE SCIENCES: COMPANY OVERVIEW
TABLE 945
ACCULAB LIFE SCIENCES: SERVICES/SOLUTIONS OFFERED
TABLE 946
NOVOTECH: COMPANY OVERVIEW
TABLE 947
NOVOTECH: SERVICES/SOLUTIONS OFFERED
TABLE 948
NOVOTECH HEALTH HOLDINGS: DEALS, JANUARY 2023–MARCH 2026
TABLE 949
LINICAL: COMPANY OVERVIEW
TABLE 950
LINICAL: SERVICES/SOLUTIONS OFFERED
TABLE 951
LINICAL: EXPANSIONS, JANUARY 2023–MARCH 2026
TABLE 952
ADVANCED CLINICAL: COMPANY OVERVIEW
TABLE 953
ADVANCED CLINICAL: SERVICES/SOLUTIONS OFFERED
TABLE 954
ADVANCED CLINICAL: DEALS, JANUARY 2023–MARCH 2026
TABLE 955
IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
TABLE 956
CRO SERVICES MARKET: RISK ANALYSIS
LIST OF FIGURES
FIGURE 1
MARKET SCENARIO
FIGURE 2
GLOBAL CRO SERVICES MARKET, 2024–2031
FIGURE 3
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CRO SERVICES MARKET, 2023–2026
FIGURE 4
DISRUPTIONS INFLUENCING THE GROWTH OF THE CRO SERVICES MARKET
FIGURE 5
HIGH-GROWTH SEGMENTS IN CRO SERVICES MARKET, 2026–2031
FIGURE 6
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN THE CRO SERVICES MARKET, IN TERMS OF VALUE, DURING THE FORECAST PERIOD
FIGURE 7
INCREASING SIZE OF THE CLINICAL DEVELOPMENT PIPELINE TO PROPEL MARKET GROWTH
FIGURE 8
US AND SMALL MOLECULES SEGMENT COMMANDED LARGEST MARKET SHARES IN 2025
FIGURE 9
CHINA TO REGISTER HIGHER CAGR DURING FORECAST PERIOD
FIGURE 10
DRIVERS, OPPORTUNITIES, AND CHALLENGES: CRO SERVICES MARKET
FIGURE 11
ACTIVE PHARMACEUTICAL PIPELINE, 2015–2026
FIGURE 12
PORTER’S FIVE FORCES ANALYSIS: CRO SERVICES MARKET
FIGURE 13
CRO SERVICES MARKET: VALUE CHAIN ANALYSIS
FIGURE 14
CRO SERVICES MARKET: ECOSYSTEM ANALYSIS
FIGURE 15
INDICATIVE PRICING ANALYSIS (PER STUDY), BY REGION, 2025 (USD MILLION)
FIGURE 16
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS IN CRO SERVICES MARKET
FIGURE 17
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES, BY MODALITY
FIGURE 18
KEY BUYING CRITERIA FOR CRO SERVICES ACROSS END USERS
FIGURE 19
DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2024 VS. 2025
FIGURE 20
CANCER (%) AS A PROPORTION OF PIPELINE IN DEVELOPMENT, 2013–2024
FIGURE 21
ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)
FIGURE 22
ANNUAL DRUG APPROVALS BY FDA CENTER FOR DRUG EVALUATION AND RESEARCH, 2013–2025
FIGURE 23
R&D SPENDING OF PHRMA MEMBER COMPANIES, 2013–2024
FIGURE 24
US FDA DE NOVO MEDICAL DEVICE APPROVALS, 2012–2024
FIGURE 25
NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT
FIGURE 26
GLOBAL DISTRIBUTION OF R&D COMPANIES, JANUARY 2025 VS. JANUARY 2026
FIGURE 27
ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT
FIGURE 28
REVENUE ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET (2021–2025)
FIGURE 29
MARKET SHARE ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET (2025)
FIGURE 30
CRO SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 31
CRO SERVICES MARKET: COMPANY FOOTPRINT
FIGURE 32
CRO SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 33
EV/EBITDA OF KEY VENDORS
FIGURE 34
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 35
CRO SERVICES MARKET: SERVICE COMPARATIVE ANALYSIS
FIGURE 36
IQVIA INC.: COMPANY SNAPSHOT (2025)
FIGURE 37
ICON PLC: COMPANY SNAPSHOT (2024)
FIGURE 38
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
FIGURE 39
LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2025)
FIGURE 40
FORTREA, INC.: COMPANY SNAPSHOT
FIGURE 41
WUXI APPTEC: COMPANY SNAPSHOT
FIGURE 42
CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
FIGURE 43
PHARMARON: COMPANY SNAPSHOT
FIGURE 44
MEDPACE: COMPANY SNAPSHOT
FIGURE 45
SGS SA: COMPANY SNAPSHOT
FIGURE 46
FRONTAGE LABS: COMPANY SNAPSHOT
FIGURE 47
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
FIGURE 48
TIGERMED: COMPANY SNAPSHOT
FIGURE 49
CRO SERVICES MARKET: RESEARCH DESIGN
FIGURE 50
CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES (DEMAND- AND SUPPLY-SIDE PARTICIPANTS)
FIGURE 51
GLOBAL CRO SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 52
GLOBAL CRO SERVICES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025
FIGURE 53
ILLUSTRATIVE EXAMPLE OF IQVIA INC.: REVENUE SHARE ANALYSIS, 2025
FIGURE 54
CRO SERVICES MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 55
TOP-DOWN APPROACH
FIGURE 56
GLOBAL CRO SERVICES MARKET: CAGR PROJECTIONS, 2026–2031
FIGURE 57
CRO SERVICES MARKET: DATA TRIANGULATION METHODOLOGY
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global CRO services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The market for companies offering CRO services is derived from secondary data from paid and unpaid sources, analysis of the service portfolios of leading companies in the ecosystem, and rating of companies by performance and quality. Various sources were consulted during the secondary research process to identify & collect information for this study. The secondary sources include annual reports, company investor presentations, white papers, journals, certified publications, articles by recognized authors, directories, and databases. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from market & technology-oriented perspectives. Secondary data were analyzed to determine the overall size of the global CRO services market, and the findings were validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global CRO services market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and medical device companies, and experts from the supply side, such as C-level and D-level executives, and trial managers. These interviews were conducted across regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World (including Latin America, the Middle East, and Africa). This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
In the complete market engineering process, the top-down & bottom-up approaches were extensively used, along with several data triangulation methods, to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analyses were performed on the complete market engineering process to present key information/insights throughout the report.
BREAKDOWN OF PRIMARIES
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down & bottom-up approaches were used to estimate and validate the total size of the CRO services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Bottom-up & Top-down Approach
The total market was divided into several segments and subsegments after determining the overall market size through estimation.
Data Triangulation
After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
CROs outsource research services to several pharmaceutical & biotechnology companies, medical device companies, and academic institutes. These services include clinical research, early-phase development, laboratory services, consulting, and data management. A sponsor (i.e., a company investigating the safety and efficacy of new drugs, therapies, or medical devices) partners with a CRO on a contractual or project-by-project basis. The CRO provides advice & guidance for planning, designing, and executing clinical trials; it offers a comprehensive and diverse range of services for each trial phase.
Key Stakeholders
- Contract Research Organizations (CROs)
- Clinical Trial Service Providers
- Pharmaceutical & Biopharmaceutical Companies
- Medical Device Manufacturing Companies
- Academic & Research Institutes
- Venture Capitalists & Investors
- Market Research & Consulting Firms
- Government Associations
- Medical Institutions & Universities
Report Objectives
- To define, describe, and forecast the CRO services market based on service type, therapeutic area, modality, delivery model, end user, and region
- To provide detailed information regarding the primary factors influencing market growth, such as drivers, restraints, opportunities, and challenges
- To strategically analyze the micromarkets concerning individual growth trends, prospects, and contributions to the overall CRO services market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To analyze subsegments of the market concerning individual growth trends, prospects, and contributions to the overall market
- To forecast the revenue of the market segments concerning six regions, namely, North America (US and Canada), Europe (Germany, UK, France, Italy, Spain, and the Rest of Europe), the Asia Pacific (China, Japan, India, Australia, South Korea and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America, the Middle East (GCC and Rest of Middle East), and Africa
- To profile the key market players and comprehensively analyze their market shares and core competencies
- To track & analyze competitive developments such as service launches, agreements, partnerships, acquisitions, business expansions, and research & development activities in the CRO services market.
Available customizations:
With the given market data, MarketsandMarkets offers customizations to meet the company’s needs. The following customization options are available for this report:
Company Information
- Detailed analysis & profiling of additional market players (up to three).
Geographic Analysis
- A further breakdown of the Rest of Asia Pacific’s CRO services market into countries
- A further breakdown of the Rest of Europe’s CRO services market into countries
- A further breakdown of the Rest of Latin America’s CRO services market into countries
- A further breakdown of the Rest of the Middle East’s CRO services market into countries
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Contract Research Organization (CRO) Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Growth opportunities and latent adjacency in Contract Research Organization (CRO) Services Market
James
Jun, 2022
Which are the driving factors of the contract research organization services market?.
John
Jun, 2022
Who are the major players operating in the contract research organization services market?.
Kahlill
Jun, 2022
Which region will lead the global contract research organization services market?.
Emily
Jun, 2026
After going through the Contract Research Organization Services Market report, I found the shift toward strategic outsourcing and integrated service models particularly relevant for mid-sized pharma companies trying to optimize development timelines without expanding internal infrastructure..
Daniel
Jun, 2026
What stood out to me in the Contract Research Organization Services Market analysis is how clinical trial complexity and regulatory pressure are driving demand for specialized CRO capabilities, especially in areas like oncology and rare diseases where expertise directly impacts trial success rates..
Lucas
Jun, 2026
From an investment perspective, reviewing the Contract Research Organization Services Market gave me a clearer view of how consolidation trends and partnerships are shaping competitive positioning, making CROs with end-to-end offerings more attractive for long-term growth..